Trial intelligence / Profile preview

Panitumumab + FOLFOX in Metastatic Colorectal Cancer (PULSE)

NCT01288339Phase 2Completed

Sponsor
GEMCAD
Start
Nov 2010
Primary completion
Feb 2015
Modality
Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
Countries
1
01

Overview

A Phase 2 trial of panitumumab in metastatic colorectal cancer (mCRC), sponsored by GEMCAD. Started Nov 2010; status: completed.

02

Drugs

panitumumab
03

Conditions

metastatic colorectal cancer (mCRC)

Beyond the preview

Go deeper on NCT01288339.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01288339.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call